Syros Pharmaceuticals (SYRS) vs. Arcus Biosciences (RCUS) Head to Head Analysis

Share on StockTwits

Syros Pharmaceuticals (NASDAQ:SYRS) and Arcus Biosciences (NYSE:RCUS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, profitability and institutional ownership.

Valuation & Earnings

This table compares Syros Pharmaceuticals and Arcus Biosciences’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Syros Pharmaceuticals $2.05 million 117.00 -$62.28 million ($1.91) -3.83
Arcus Biosciences $8.35 million 66.77 -$49.59 million ($1.43) -8.76

Arcus Biosciences has higher revenue and earnings than Syros Pharmaceuticals. Arcus Biosciences is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations for Syros Pharmaceuticals and Arcus Biosciences, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Syros Pharmaceuticals 0 1 5 0 2.83
Arcus Biosciences 0 0 2 0 3.00

Syros Pharmaceuticals currently has a consensus price target of $15.33, indicating a potential upside of 109.47%. Arcus Biosciences has a consensus price target of $21.00, indicating a potential upside of 67.73%. Given Syros Pharmaceuticals’ higher possible upside, equities analysts plainly believe Syros Pharmaceuticals is more favorable than Arcus Biosciences.

Insider and Institutional Ownership

67.9% of Syros Pharmaceuticals shares are held by institutional investors. Comparatively, 49.1% of Arcus Biosciences shares are held by institutional investors. 27.8% of Syros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Syros Pharmaceuticals and Arcus Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Syros Pharmaceuticals -3,038.00% -64.43% -51.17%
Arcus Biosciences -594.39% -19.83% -17.11%

Summary

Arcus Biosciences beats Syros Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients. It has target discovery, research collaboration, and option agreement with Incyte to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co., Ltd. for the development and commercialization of SY-1425. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.

About Arcus Biosciences

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody. The company was founded in 2015 and is headquartered in Hayward, California.

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.